Despite the aggressive nature of Non-Small Cell Lung Cancer (NSCLC), circulating tumor cells that lead to metastases often go undetected in the blood. ISB researchers in Dr. Wei Wei’s lab and their collaborators have developed a novel method to better detect these circulating cells.
ISB research sheds light on how interspecies interactions arise, evolve and are maintained. The results, published in The ISME Journal, provide a new window to understand the key roles of these interactions in industrial applications, and in the health and disease of humans, animals and plants.
The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals.
Since October, 50 high school teachers representing several school districts across Washington have participated in a series of ISB workshops. “We quickly realized we were in a unique position to help educators pivot into remote teaching,” said Caroline Kiehle.
Providence President and CEO Dr. Rod Hochman joined ISB President and Professor Dr. Jim Heath for an hour-long conversation hosted by ISB and Town Hall Seattle about how healthcare and science will be different in a post-pandemic world.
NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.
ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.
CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.
Wait, what day is it? What month is it? This year has been a doozy. The pandemic has fundamentally changed our lives, and at times, has made us feel like we’re in a real-life Groundhog Day. Well, if you’ve found yourself in the last-minute shopping scramble, we’re back with a half dozen solid ideas that we hope will make your gift-giving life easier.
GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.
ISB researchers Dr. Nitin Baliga, Dr. Eliza Peterson and Dr. Vivek Srinivas have developed a new cell sorting technology, called PerSort, that isolates and characterizes dormant persisters that exist in cultures of Mycobacterium tuberculosis, the pathogen that causes tuberculosis.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
While scientists have long studied bacterial infections, less attention has been paid to how the host immune response affects bacterial gene expression in the body. In a just-published paper in PNAS, ISB researchers detailed how the bacterium Salmonella conceals itself from the host immune system.
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
Dr. David Eagleman — bestselling author, TV personality, CEO of Neosensory, adjunct professor at Stanford, TED speaker, and more — was the featured guest at the ISB-Town Hall Seattle event focusing on brain health. His presentation was titled “Can We Create New Senses for Humans?”
Like the draft “shotgun” Human Genome Project of the Human Genome Organization (HUGO), the HPP has now reached a significant decadal milestone of more than 90 percent completion of the Human Proteome that is referred to as the human proteome “parts list.”
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
Everybody pees and poops. What if there was a way to use the byproducts of our everyday bodily functions to understand the general health of a population? That is exactly what MIT’s Dr. Eric Alm is pursuing. In an ISB-Town Hall Seattle live stream, Alm discussed the promise of this novel form of public health tracking.
